HIV/AIDS-related lymphoma: perspective from a regional cancer center in India.

Conclusion: ARL is a heterogeneous disease. Histologic subtype is a major determinant of the clinical outcome. ADL has significantly lower CD4 counts than those of NADL. There is an urgent and unmet need for uniform management guidelines for improving outcomes in this under-represented patient population. PMID: 31730692 [PubMed]
Source: Blood Research - Category: Hematology Tags: Blood Res Source Type: research

Related Links:

The objective of this review was to determine whether in previously untreated adults with HL (all stages) receiving first-line therapy, interim PET scan results (i.e. a positive or a negative result) can distinguish between those with a poor prognosis and those with a better prognosis, and thereby predict survival in each group.How many studies were included? What was included and what was excluded?We included twenty-three studies in total, in this review. In all studies, interim PET was conducted during first-line therapy and after two, three, and/or four cycles of chemotherapy in adults with HL (all stages). We included ...
Source: Cochrane News and Events - Category: Information Technology Authors: Source Type: news
This article reviews the diagnostic features and summarizes current biologic understanding of HIV-associated lymphomas.
Source: Surgical Pathology Clinics - Category: Pathology Authors: Source Type: research
Segun Fatumo1,2,3*, Tommy Carstensen4, Oyekanmi Nashiru3, Deepti Gurdasani4†, Manjinder Sandhu4,5† and Pontiano Kaleebu1,2† 1Uganda Medical Informatics Centre, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda 2London School of Hygiene and Tropical Medicine, London, United Kingdom 3H3Africa Bioinformatics Network (H3ABioNet) Node, Centre for Genomics Research and Innovation, NABDA/FMST, Abuja, Nigeria 4Human Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, United Kingdom 5Division of Computational Medicine, Department of Medicine, University of Cambridge, Cambridge, United Kin...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Conclusions Epidemiological studies have repeatedly helped identify definitive triggers for several diseases. As highlighted in this perspective report, previous studies strongly argue for the interplay between intrinsic factors and putative preventable extrinsic triggers/promoters for CTCL. Given the evidence of geographical regional clustering of CTCL patients, CTCL occurrence in unrelated family members and recent evidence implicating S. aureus in the pathogenesis/progression of CTCL, more research is needed to decipher the precise mechanism by which specific environmental exposures may be driving the pathogenesis of t...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions The major challenges in the development of adoptive cell therapy for T cell tumors, as mentioned above, remain fratricide, T cell aplasia and the potential for leukemic transduction or poor T cell function if used in the autologous setting. Approaches to overcome fratricide include the genetic modification and deletion of the T cell antigen in the case of long-term CAR-T cell persistence or regulated CAR-T expression. To ensure restoration of T cell immunity, transient CAR expression can be achieved incorporation of a CAR suicide gene, transient CAR expression using mRNA electroporation, or short-lived NK cell...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Discussion Suppressor of cytokine signaling 1 is an essential molecule for maintaining immune homeostasis and subverting inflammation. Disorders arising from excess inflammation or SOCS1 deficiency can be potentially treated with SOCS1 mimetics (Ahmed et al., 2015). While SOCS1 has promising potential in many disorders, it should be noted that new targets and actions of SOCS1 are still being discovered and not all the effects of this protein are beneficial in autoimmune diseases and cancer. For instance, SOCS1 degrades IRS1 and IRS2, required for insulin signaling, via the SOCS Box domain, thus, limiting its potential in ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
A man in London has become only the second person to achieve remission from HIV infection, researchers from the UK reported Tuesday. The therapy responsible has worked on only one other person who is considered to be “cured” of HIV: Timothy Ray Brown, who still does not show signs of the virus in his body after more than 10 years. Here’s what to know about the landmark case. How did it happen? In a letter published in the journal Nature, researchers led by Ravindra Gupta from the University of Cambridge London and Imperial College London and his colleagues say that they used a treatment similar to the one...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized HIV/AIDS Source Type: news
Doctors say a British man who previously tested positive for HIV might be the second person ever to be cured of the virus that causes AIDS. Reuters reports that the man, whose identity has not been revealed, has tested negative for the virus almost three years after he received a bone marrow transplant from a donor with an HIV-resistant genetic mutation. The man stopped taking antiretroviral drugs 18 months ago. “There is no virus there that we can measure. We can’t detect anything,” Ravindra Gupta, the doctor who co-lead the man’s treatment team, told Reuters. The man, who has been dubbed the &ldqu...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized health HIV/AIDS onetime overnight Source Type: news
Doctors say a British man who previously tested positive for HIV might be the second person ever to be cured of the AIDS virus. Reuters reports that the man, whose identity has not been revealed, has tested negative for the virus almost three years after he received a bone marrow transplant from a donor with an HIV-resistant genetic mutation. The man stopped taking antiretroviral drugs 18 months ago. “There is no virus there that we can measure. We can’t detect anything,” Ravindra Gupta, the doctor who co-lead the man’s treatment team, told Reuters. The man, who has been dubbed the “London pat...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized health HIV/AIDS onetime overnight Source Type: news
Publication date: Available online 27 February 2019Source: The Lancet HIVAuthor(s): Raúl U Hernández-Ramírez, Li Qin, Haiqun Lin, Wendy Leyden, Romain S Neugebauer, Keri N Althoff, Chad J Achenbach, Nancy A Hessol, Gypsyamber D'Souza, Kelly A Gebo, M John Gill, Surbhi Grover, Michael A Horberg, Jun Li, W Christopher Mathews, Angel M Mayor, Lesley S Park, Charles S Rabkin, Kate Salters, Amy C JusticeSummaryBackgroundResearch is needed to better understand relations between immunosuppression and HIV viraemia and risk for non-Hodgkin lymphoma, a common cancer in people living with HIV. We aimed to identif...
Source: The Lancet HIV - Category: Infectious Diseases Source Type: research
More News: Cancer | Cancer & Oncology | Epidemiology | Hematology | HIV AIDS | Hodgkin's Disease | India Health | Lymphoma | Statistics | Study